Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 2/3 1Phase 1 1

Status

Unknown 2Recruiting 2Completed 2Terminated 1

Sponsor Class

OTHER 7

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Gastrointestinal 7

Conditions

Leukemia, Myeloid, Acute 100Leukemia 36Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Myelodysplastic Syndromes 17Leukemia, Monocytic, Acute 14Leukemia, Myelomonocytic, Acute 13Leukemia, Erythroblastic, Acute 12Leukemia, Megakaryoblastic, Acute 11Congenital Abnormalities 11Leukemia, Promyelocytic, Acute 9Recurrence 8Leukemia, Biphenotypic, Acute 7Carcinoma, Hepatocellular 7Leukemia, Myelomonocytic, Chronic 6Myeloproliferative Disorders 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Anemia, Refractory, with Excess of Blasts 5Lymphoma 4Blast Crisis 4Neoplasm, Residual 3Lymphoma, Large B-Cell, Diffuse 3Liver Neoplasms 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Eosinophilic, Acute 3Leukemia, Basophilic, Acute 3Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Follicular 2Lung Neoplasms 2

Interventions

Sorafenib 131lenvatinib 115Bevacizumab 88Radiosurgery 69atezolizumab 55sintilimab 54Nivolumab 51durvalumab 43Hepatectomy 43Fluorouracil 42apatinib 41Oxaliplatin 41camrelizumab 38Radiofrequency Ablation 38pembrolizumab 36Radiotherapy 36tislelizumab 35Leucovorin 31Magnetic Resonance Spectroscopy 30Immune Checkpoint Inhibitors 28Doxorubicin 28Folfox protocol 26tremelimumab 25regorafenib 25Cisplatin 20spartalizumab 19donafenib 19Gemcitabine 19Cyclophosphamide 19toripalimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Hepatocellular × Idarubicin × Clear all
NCT03727633 2026-03-31

LIDA-BII

University Hospital, Montpellier

Phase 2 Terminated
44 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06492408 2024-07-09

Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

Second Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting
90 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06482801 2024-07-01

Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT

Second Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting
90 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05280444 2022-12-29

Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma

Zhongda Hospital

Phase 2/3 Unknown
216 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05053386 2021-09-22

Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma

Zhejiang Cancer Hospital

Phase NA Unknown
186 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03349957 2018-04-25

TANDEM-IDA

University Hospital, Montpellier

Completed
98 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01040559 2013-01-09

Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas

Centre Hospitalier Universitaire Dijon

Phase 1 Completed
18 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡